United Kingdom: Food, Drugs, Healthcare, Life Sciences

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

Following widespread litigation over Halozyme's SPC families for Herceptin Hylecta and MabThera, Europe's highest court received a critical referral addressing whether recombinant human hyaluronidase can be considered an "active ingredient" despite its classification as an excipient in marketing authorisation documents. Advocate General Emiliou has now published a significant legal opinion proposing that substances expressly designated as excipients cannot be regarded as active ingredients for SPC purposes.

The UK pharmaceutical sector faces significant challenges from counterfeit medicines that threaten patient safety and undermine legitimate supply chains. This analysis examines the current landscape of pharmaceutical counterfeiting...

The upcoming UK general election on 4 July 2024 represents a pivotal moment for the healthcare and life sciences sectors. Stakeholders in the Life Sciences sector have been looking for policies that could address the impact of Brexit and provide a regulatory landscape to encourage innovation, in particular in the area of the use of artificial intelligence (AI) in medical technologies.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The COVID-19 pandemic thrust mRNA technology into the global spotlight, transforming decades of foundational research into commercially valuable vaccines almost overnight. This rapid commercialization, combined with enormous revenues and a complex web of overlapping patents, has triggered an unprecedented wave of intellectual property disputes that is reshaping how value is allocated across the biotechnology industry and determining who controls access to next-generation RNA-based medicines.

The upcoming UK general election on 4 July 2024 represents a pivotal moment for the healthcare and life sciences sectors. Stakeholders in the Life Sciences sector have been looking for policies that could address the impact of Brexit and provide a regulatory landscape to encourage innovation, in particular in the area of the use of artificial intelligence (AI) in medical technologies.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The Ockenden Review has uncovered serious and repeated concerns in maternity care at Nottingham University Hospitals, spanning thousands of cases from 2012 to 2025. With findings identifying systemic failures in patient safety, clinical practice, and organisational culture, the review raises critical questions about whether improved care could have prevented devastating outcomes for affected families.